Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 29.10 | -0.21% | -0.06 |
Earnings due: May 23
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 200 DMA | Bullish | -0.21% | |
| Pocket Pivot | Bullish Swing Setup | -0.21% | |
| Outside Day | Range Expansion | -0.21% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Fell Below 200 DMA | 1 day ago |
| Down 1% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/23/2024
Supernus Pharmaceuticals, Inc. Description
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drug Discovery Clinical Research Clinical Trial Chloride Epilepsy Depression Neurology Attention Deficit Hyperactivity Disorder Clinical Trial Product Hyperactivity Disorder Central Nervous System Disease Treatment Of Depression Treatment Of Epilepsy Investigational New Drug Treatment Of Central Nervous System Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.94 |
| 52 Week Low | 22.0 |
| Average Volume | 450,703 |
| 200-Day Moving Average | 29.04 |
| 50-Day Moving Average | 31.49 |
| 20-Day Moving Average | 29.93 |
| 10-Day Moving Average | 29.75 |
| Average True Range | 1.29 |
| RSI (14) | 42.53 |
| ADX | 19.14 |
| +DI | 11.30 |
| -DI | 23.68 |
| Chandelier Exit (Long, 3 ATRs) | 29.00 |
| Chandelier Exit (Short, 3 ATRs) | 31.87 |
| Upper Bollinger Bands | 31.36 |
| Lower Bollinger Band | 28.50 |
| Percent B (%b) | 0.21 |
| BandWidth | 9.55 |
| MACD Line | -0.51 |
| MACD Signal Line | -0.43 |
| MACD Histogram | -0.0788 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.03 | ||||
| Resistance 3 (R3) | 30.00 | 29.66 | 29.88 | ||
| Resistance 2 (R2) | 29.66 | 29.42 | 29.68 | 29.82 | |
| Resistance 1 (R1) | 29.38 | 29.28 | 29.21 | 29.41 | 29.77 |
| Pivot Point | 29.04 | 29.04 | 28.96 | 29.06 | 29.04 |
| Support 1 (S1) | 28.76 | 28.80 | 28.59 | 28.79 | 28.43 |
| Support 2 (S2) | 28.42 | 28.66 | 28.44 | 28.38 | |
| Support 3 (S3) | 28.14 | 28.42 | 28.33 | ||
| Support 4 (S4) | 28.17 |
